Zenkuda and Tabirafusp-ted Both Hit Primary Endpoints in Pivotal DAYBREAK Trial
KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.2× avg).
Summary
Kodiak Sciences announced that both Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK trial for wet AMD. Zenkuda demonstrated 6-month durability in 54% of patients and a clean safety profile. The company plans a Q4 2026 BLA submission for Zenkuda across three indications.
Key Events · Product Development and Regulatory · KOD
-
Both Drugs Hit Primary Endpoints
Zenkuda met the DAYBREAK primary endpoint with p=0.0007; tabirafusp-ted met its vision primary endpoint with p=0.0036 and anatomical key secondary endpoint with p<0.0001.
-
Zenkuda Shows 6-Month Durability
54% of Zenkuda patients achieved a 24-week dosing interval at year one using strict treat-to-dryness retreatment criteria, with 0% intraocular inflammation and 0.5% cataract adverse event rate.
-
BLA Submission Planned Q4 2026
Kodiak plans to submit a multi-indication BLA for Zenkuda in Q4 2026 covering five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion.
-
KSI-101 Data Readout December 2026
Topline data from the Phase 3 PEAK study of KSI-101 in macular edema secondary to inflammation is expected in December 2026, with a BLA filing planned for Q2 2027.
Analysis · KOD · Life Sciences
Both Zenkuda and tabirafusp-ted met their primary endpoints in the Phase 3 DAYBREAK trial for wet AMD. Zenkuda showed 54% of patients achieving 6-month dosing intervals and a 0% intraocular inflammation rate. The company plans a multi-indication BLA submission for Zenkuda in Q4 2026 covering five positive Phase 3 studies. This is a thesis-altering event for a precommercial biotech that had a going-concern warning as recently as August 2026 — positive pivotal data across multiple indications dramatically de-risks the pipeline and opens a path to commercialization.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 41.9% of the 322 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KOD was trading at $60.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.94 to $47.84. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.